Hims & Hers Health Sees $744 Million Trading Volume Despite Analyst Skepticism

On April 2, 2025, Hims & Hers Health (HIMS) saw a trading volume of $744 million, marking a 48.84% decrease from the previous day. Despite this, the stock managed to close with a fractional gain, rising 0.55% and marking its third consecutive day of gains, with a total increase of 7.14% over the past three days.

Hims & Hers Health has recently expanded its weight-loss offerings by adding Eli Lilly's weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform. This move has been well-received by investors, contributing to the stock's recent gains.

However, the excitement surrounding the new product offerings was tempered by a lukewarm analyst note. Truist Securities analyst Jailendra Singh reiterated his hold recommendation on the stock, speculating that much of the excitement was due to the erroneous assumption that the tirzepatide arrangement is a formal collaboration between Hims & Hers and Eli Lilly. While Singh believes the new products will help boost the company's fundamentals, he does not feel they will make a significant difference.